海思科 (002653.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

144.8x

Market Cap

CNY 73.20B

MomentumView details →

1D Return

−3.59%

YTD Return

+34.82%

RSI (14)

56.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

144.8x

Market Cap

CNY 73.20B

RSI (14)

56.1

MomentumView details →

1D Return

−3.59%

YTD Return

+34.82%

ProfitabilityView details →

Gross Margin

74.48%

Net Margin

15.17%

EBITDA Margin

10.67%

ROE (TTM)

15.84%

ROA (TTM)

10.02%

Asset Turnover

0.69x

GrowthView details →

Revenue YoY

+31.04%

EPS YoY

+122.19%

FCF YoY

+2264.34%

Revenue CAGR 3Y

+13.32%

EPS CAGR 3Y

−4.00%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.26

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

−1.19%

Capital & dividendView details →

Debt/Equity

0.22x

Current Ratio

2.02x

Quick Ratio

1.81x

Div Yield

1.15%

Div Rate

CNY 0.79

Div Growth 1Y

+193.70%

Financials snapshotView financials →

Revenue (TTM)

5.06B

Net Income (TTM)

767.58M

Op. CF (TTM)

1.12B

Next earningsNov 4, 2026 →

Latest newsMore news →

Haisco licensed its preclinical immunology asset to Sentivera in a deal valued at more than $1.5 billion.9d ago

Haisco Pharmaceutical proposed a cash dividend of 5.26 yuan per 10 shares (tax included) to all shareholders, based on a base of 1.141 billion shares.9d ago

Similar companies

恒逸石化000703.SZ 光库科技300620.SZ 广合科技001389.SZ 中信特钢000708.SZ 圣邦股份300661.SZ 鼎龙股份300054.SZ Find similar companies →

Latest newsMore news →

Haisco licensed its preclinical immunology asset to Sentivera in a deal valued at more than $1.5 billion.9d ago Haisco Pharmaceutical proposed a cash dividend of 5.26 yuan per 10 shares (tax included) to all shareholders, based on a base of 1.141 billion shares.9d ago